Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00110019 Mucosal Melanom...
Recurrent Melan...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Carboplatin
Laboratory Biom...
Paclitaxel
Pharmacological...
Placebo
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI) View Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma NCT01961115 Mucosal Melanom...
Recurrent Melan...
Recurrent Uveal...
Stage IIIA Skin...
Stage IIIA Uvea...
Stage IIIB Skin...
Stage IIIB Uvea...
Stage IIIC Skin...
Stage IIIC Uvea...
Stage IV Skin M...
Stage IV Uveal ...
Epacadostat
MELITAC 12.1 Pe...
18 Years - Fred Hutchinson Cancer Center View Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy NCT02857374 Stage IB Skin M...
Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Diagnostic Micr...
Fluorescein Sod...
Laboratory Biom...
Sentinel Lymph ...
18 Years - Roswell Park Cancer Institute View Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma NCT01744171 Recurrent Melan...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Recombinant Hum...
Laboratory Biom...
18 Years - Roswell Park Cancer Institute View Recombinant Interferon Alfa-2b in Treating Patients With Melanoma NCT01460875 Stage IA Skin M...
Stage IB Skin M...
Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
recombinant int...
laboratory biom...
12 Years - Ohio State University Comprehensive Cancer Center View Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification NCT02812693 Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Imatinib Mesyla...
Laboratory Biom...
Pembrolizumab
18 Years - Ohio State University Comprehensive Cancer Center View Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery NCT01989559 Recurrent Melan...
Stage IA Skin M...
Stage IB Skin M...
Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
gp100:209-217(2...
HPV 16 E7:12-20...
Laboratory Biom...
- National Cancer Institute (NCI) View Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma NCT00397982 Recurrent Melan...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Bevacizumab
Laboratory Biom...
Temsirolimus
Therapeutic Con...
18 Years - National Cancer Institute (NCI) View Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery NCT01989559 Recurrent Melan...
Stage IA Skin M...
Stage IB Skin M...
Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
gp100:209-217(2...
HPV 16 E7:12-20...
Laboratory Biom...
- National Cancer Institute (NCI) View Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy NCT03719131 Cutaneous Melan...
Cutaneous Melan...
Stage III Melan...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Unresectable Me...
Nivolumab
Rituximab and H...
Ipilimumab
18 Years - Emory University View Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification NCT02812693 Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Imatinib Mesyla...
Laboratory Biom...
Pembrolizumab
18 Years - Ohio State University Comprehensive Cancer Center View Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00110019 Mucosal Melanom...
Recurrent Melan...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Carboplatin
Laboratory Biom...
Paclitaxel
Pharmacological...
Placebo
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI) View Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 Adult Anaplasti...
Adult Anaplasti...
Adult Anaplasti...
Adult Brain Ste...
Adult Giant Cel...
Adult Glioblast...
Adult Gliosarco...
Adult Mixed Gli...
Adult Solid Neo...
Male Breast Car...
Recurrent Adult...
Recurrent Breas...
Recurrent Colon...
Recurrent Melan...
Recurrent Non-S...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Recta...
Recurrent Renal...
Stage III Pancr...
Stage III Renal...
Stage IIIA Colo...
Stage IIIA Non-...
Stage IIIA Ovar...
Stage IIIA Ovar...
Stage IIIA Rect...
Stage IIIA Skin...
Stage IIIB Brea...
Stage IIIB Colo...
Stage IIIB Non-...
Stage IIIB Ovar...
Stage IIIB Ovar...
Stage IIIB Rect...
Stage IIIB Skin...
Stage IIIC Brea...
Stage IIIC Colo...
Stage IIIC Ovar...
Stage IIIC Ovar...
Stage IIIC Rect...
Stage IIIC Skin...
Stage IV Breast...
Stage IV Non-Sm...
Stage IV Ovaria...
Stage IV Ovaria...
Stage IV Pancre...
Stage IV Renal ...
Stage IV Skin M...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Gamma-Secretase...
Cediranib Malea...
Pharmacological...
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma NCT03028948 Stage 0 Skin Me...
Stage I Skin Me...
Stage IA Skin M...
Stage IB Skin M...
Stage II Skin M...
Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage III Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Internet-Based ...
Questionnaire A...
Survey Administ...
18 Years - Rutgers, The State University of New Jersey View Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma NCT03229278 Lymphoma
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Recurrent Bladd...
Recurrent Class...
Recurrent Head ...
Recurrent Lymph...
Recurrent Malig...
Recurrent Renal...
Stage III Bladd...
Stage III Lymph...
Stage III Non-S...
Stage III Renal...
Stage III Skin ...
Stage IIIA Non-...
Stage IIIA Skin...
Stage IIIB Non-...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Bladde...
Stage IV Lympho...
Stage IV Non-Sm...
Stage IV Renal ...
Stage IV Skin M...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable He...
Unresectable So...
Enzyme Inhibito...
Laboratory Biom...
Nivolumab
Pembrolizumab
18 Years - Rutgers, The State University of New Jersey View Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners NCT03112668 Malignant Femal...
Malignant Hepat...
Partner
Stage III Breas...
Stage III Cervi...
Stage III Color...
Stage III Lung ...
Stage III Prost...
Stage III Skin ...
Stage III Uteri...
Stage IIIA Brea...
Stage IIIA Cerv...
Stage IIIA Colo...
Stage IIIA Lung...
Stage IIIA Skin...
Stage IIIA Uter...
Stage IIIB Brea...
Stage IIIB Cerv...
Stage IIIB Colo...
Stage IIIB Lung...
Stage IIIB Skin...
Stage IIIB Uter...
Stage IIIC Brea...
Stage IIIC Colo...
Stage IIIC Skin...
Stage IIIC Uter...
Stage IV Breast...
Stage IV Cervic...
Stage IV Colore...
Stage IV Lung C...
Stage IV Prosta...
Stage IV Skin M...
Stage IV Uterin...
Stage IVA Cervi...
Stage IVA Color...
Stage IVA Uteri...
Stage IVB Cervi...
Stage IVB Color...
Stage IVB Uteri...
Cognitive Behav...
Quality-of-Life...
Questionnaire A...
Survey Administ...
18 Years - Rutgers, The State University of New Jersey View MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery NCT02320305 Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
MART-1 Antigen
TLR4 Agonist GL...
Laboratory Biom...
18 Years - Mayo Clinic View MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery NCT02320305 Stage IIA Skin ...
Stage IIB Skin ...
Stage IIC Skin ...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
MART-1 Antigen
TLR4 Agonist GL...
Laboratory Biom...
18 Years - Mayo Clinic View Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma NCT00019682 Recurrent Melan...
Stage IIIA Skin...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Skin M...
Aldesleukin
gp100 Antigen
Montanide ISA 5...
Quality-of-Life...
Questionnaire A...
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View